AbbVie (ABBV) to Acquire Apogee Therapeutics

AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics announced on June 22 their entry into a definitive agreement under which AbbVie Inc. (NYSE:ABBV) will acquire Apogee and its diverse pipeline of multiple clinical-stage candidates in development across immunological and inflammatory diseases, which includes asthma and atopic dermatitis. Management stated that the acquisition complements the company’s present immunology portfolio and bolsters its clinical presence in the respiratory space.

Canaccord Says AbbVie's (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook

The company further stated that, according to the terms of the transaction, AbbVie Inc. (NYSE:ABBV) will acquire all outstanding shares of Apogee for $135.11 per share in cash, with the transaction valuing Apogee at a total equity value of approximately $10.9 billion. The transaction was unanimously approved by the boards of directors of both companies, and management expects the transaction to close in fiscal Q3 2026. This is subject to customary closing conditions, including Apogee shareholder approval and receipt of regulatory approvals.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1